142 related articles for article (PubMed ID: 21751817)
1. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects.
Kim TH; Youn YS; Jiang HH; Lee S; Chen X; Lee KC
Bioconjug Chem; 2011 Aug; 22(8):1631-7. PubMed ID: 21751817
[TBL] [Abstract][Full Text] [Related]
2. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
[TBL] [Abstract][Full Text] [Related]
4. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
[TBL] [Abstract][Full Text] [Related]
5. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
[TBL] [Abstract][Full Text] [Related]
6. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
[TBL] [Abstract][Full Text] [Related]
7. Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis.
Kim YJ; Chae SY; Jin CH; Sivasubramanian M; Son S; Choi KY; Jo DG; Kim K; Chan Kwon I; Lee KC; Park JH
Biomaterials; 2010 Dec; 31(34):9057-64. PubMed ID: 20813405
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
9. Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer.
Byeon HJ; Choi SH; Choi JS; Kim I; Shin BS; Lee ES; Park ES; Lee KC; Youn YS
Acta Biomater; 2014 Jan; 10(1):142-50. PubMed ID: 24021228
[TBL] [Abstract][Full Text] [Related]
10. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.
Kim TH; Jo YG; Jiang HH; Lim SM; Youn YS; Lee S; Chen X; Byun Y; Lee KC
J Control Release; 2012 Sep; 162(2):422-8. PubMed ID: 22824780
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
[TBL] [Abstract][Full Text] [Related]
12. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.
Wei X; Yang X; Zhao W; Xu Y; Pan L; Chen S
Bioconjug Chem; 2017 Aug; 28(8):2180-2189. PubMed ID: 28697305
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL; Zou WY; Song LH; Wei W
Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application.
Dai C; Fu Y; Chen S; Li B; Yao B; Liu W; Zhu L; Chen N; Chen J; Zhang Q
Sci China Life Sci; 2013 Jan; 56(1):51-8. PubMed ID: 23314867
[TBL] [Abstract][Full Text] [Related]
16. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial.
Jiang J; Liu X; Deng L; Zhang P; Wang G; Wang S; Liu H; Su Y
Eur J Pharmacol; 2014 Oct; 740():722-32. PubMed ID: 24929054
[TBL] [Abstract][Full Text] [Related]
17. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.
Chae SY; Kim TH; Park K; Jin CH; Son S; Lee S; Youn YS; Kim K; Jo DG; Kwon IC; Chen X; Lee KC
Mol Cancer Ther; 2010 Jun; 9(6):1719-29. PubMed ID: 20515949
[TBL] [Abstract][Full Text] [Related]
18. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
[TBL] [Abstract][Full Text] [Related]
19. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E
Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212
[TBL] [Abstract][Full Text] [Related]
20. Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities.
Pan LQ; Zhao WB; Lai J; Ding D; Wei XY; Li YY; Liu WH; Yang XY; Xu YC; Chen SQ
Sci Rep; 2015 Oct; 5():14872. PubMed ID: 26445897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]